Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 81 Carcinoma, Non-Small-Cell Lung 76 Neoplasms 71 Ovarian Neoplasms 68 Neoplasm Metastasis 30 Fallopian Tube Neoplasms 30 Carcinoma, Ovarian Epithelial 29 Lung Neoplasms 26 Unspecified Adult Solid Tumor, Protocol Specific 24 Triple Negative Breast Neoplasms 20 Endometrial Neoplasms 20 Esophageal Neoplasms 18 Stomach Neoplasms 16 Colorectal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 13 Head and Neck Neoplasms 13 Solid Tumors 12 Small Cell Lung Carcinoma 10 Melanoma 10 Pancreatic Neoplasms 9 Uterine Cervical Neoplasms 8 Prostatic Neoplasms 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma 8 Carcinoma, Renal Cell 8 Carcinoma 8 Brenner Tumor 8 Urinary Bladder Neoplasms 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Non-Small Cell Lunch Cancer × Paclitaxel × Clear all

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡